Farxiga and Atorvastatin Interaction: What Patients and Clinicians Need to Know

Can You Take Farxiga with Atorvastatin?

Yes. Dapagliflozin and atorvastatin are co-prescribed routinely in clinical practice, and the FDA labeling for dapagliflozin does not list atorvastatin as a drug requiring dose adjustment or special precaution. [1] A dedicated pharmacokinetic study found that atorvastatin's area under the curve (AUC) increased by roughly 22% when given alongside dapagliflozin, while dapagliflozin's own AUC was unchanged. [2] That 22% change sits within the acceptable bioequivalence window and does not translate into added clinical risk for the average patient.

Why Both Drugs Are Often Prescribed Together

Type 2 diabetes carries a two-to-three-fold elevated risk of major adverse cardiovascular events compared with normoglycemic individuals. [3] Dapagliflozin addresses glycemic control, reduces heart failure hospitalizations, and slows chronic kidney disease progression. Atorvastatin lowers LDL-cholesterol and reduces cardiovascular event rates. The 2024 American Diabetes Association Standards of Medical Care state that "statin therapy is recommended for most patients with diabetes aged 40 to 75 years." [4] Co-prescription is therefore expected, not coincidental.

Prevalence of This Combination in Real-World Practice

Observational data consistently show that SGLT2 inhibitors and statins appear together in 40 to 60% of prescriptions written for patients with type 2 diabetes and established atherosclerotic cardiovascular disease. [5] Given that dapagliflozin's DECLARE-TIMI 58 trial enrolled 17,160 patients, the majority of whom were on background statin therapy, the safety record of this combination is grounded in a large, real-world-reflective dataset. [6]

How Dapagliflozin Is Metabolized (and Why CYP3A4 Is Not Relevant)

Dapagliflozin does not go through the cytochrome P450 system in any significant way. Its primary route of elimination is O-glucuronidation by UGT1A9, an enzyme found in the liver and kidneys. [1] This is the core reason why the drug has a limited interaction profile. Drugs that inhibit or induce CYP3A4, CYP2D6, or CYP2C9 generally do not affect dapagliflozin concentrations.

UGT1A9 Glucuronidation

UGT1A9 converts dapagliflozin into its inactive glucuronide metabolite (dapagliflozin 3-O-glucuronide), which is then excreted renally. [2] Atorvastatin is not a UGT1A9 inhibitor of clinical significance. No published in vitro or in vivo data show atorvastatin altering UGT1A9 activity enough to change dapagliflozin's pharmacokinetics meaningfully.

P-glycoprotein and BCRP Transporters

Dapagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). [1] Atorvastatin is itself a BCRP substrate and a weak P-gp substrate, but it is not a potent inhibitor of either transporter at standard therapeutic doses (10 to 80 mg daily). [7] In vitro inhibition constants for atorvastatin at these transporters are well above the plasma concentrations achieved clinically, meaning transporter-mediated interactions are not expected.

How Atorvastatin Is Metabolized (CYP3A4, OATP1B1, OATP1B3)

Atorvastatin is metabolized primarily by CYP3A4 and is also a substrate for the hepatic uptake transporters OATP1B1 and OATP1B3. [7] The 22% AUC increase seen in the dedicated pharmacokinetic study was likely driven by a mild inhibitory effect of dapagliflozin on one or more of these transporters rather than a CYP3A4 interaction.

Clinical Significance of a 22% AUC Increase

A 22% rise in atorvastatin exposure is small. For context, strong CYP3A4 inhibitors such as clarithromycin raise atorvastatin AUC by more than 80%, and grapefruit juice can raise it by 37 to 83% depending on quantity consumed. [8] The FDA's drug interaction guidance considers a change of <25% in AUC as unlikely to warrant dose modification for atorvastatin unless the patient has pre-existing risk factors for statin-associated muscle events (SAMS). [8] Regulatory agencies generally classify interactions below the 25% threshold as "no clinically significant interaction."

Myopathy Risk: Putting the Numbers in Context

Statin-associated muscle symptoms occur in an estimated 5 to 10% of patients on atorvastatin in observational studies, though randomized trial rates are much lower. [9] The 22% AUC increase from dapagliflozin co-administration would be expected to produce, at most, a marginal additional risk, one that is substantially below the risk conferred by genuinely interacting drugs such as cyclosporine (increases atorvastatin AUC by approximately 8.7-fold) or gemfibrozil. [7] No published case series document myopathy attributable specifically to dapagliflozin co-administration with atorvastatin.

Pharmacodynamic Interactions: Glucose, Blood Pressure, and Lipids

Beyond pharmacokinetics, clinicians should consider whether the two drugs interact at the level of clinical effects.

Blood Glucose Effects

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing glycosuria of roughly 60 to 80 grams of glucose per day. [1] Atorvastatin does not alter renal glucose handling. High-potency statins (rosuvastatin, atorvastatin) are associated with a modest increase in fasting glucose and a small increase in incident diabetes risk, the JUPITER trial (N=17,802) showed a hazard ratio of 1.25 for new-onset diabetes with rosuvastatin. [10] A similar signal exists for atorvastatin. Dapagliflozin counteracts this by lowering blood glucose, so the combination may actually be pharmacodynamically complementary rather than additive in the harmful direction. The DECLARE-TIMI 58 trial demonstrated that dapagliflozin reduced HbA1c by 0.4% versus placebo over a median follow-up of 4.2 years in a population where more than 70% were on background statin therapy. [6]

Blood Pressure Effects

Dapagliflozin reduces systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis and natriuresis. [11] Atorvastatin has no direct antihypertensive effect. Volume depletion from dapagliflozin, though mild at therapeutic doses, is worth monitoring in patients who are also on loop diuretics or ACE inhibitors, but atorvastatin does not contribute to this concern.

LDL-Cholesterol and Lipid Panel Changes

SGLT2 inhibitors produce modest increases in LDL-cholesterol. A meta-analysis of 43 randomized trials (N=26,718) found that SGLT2 inhibitors raised LDL by a mean of 2.3 mg/dL versus placebo. [12] Atorvastatin's LDL-lowering effect, typically 37 to 51% at doses of 10 to 80 mg, dwarfs this small rise, making the net lipid effect of the combination strongly favorable. [7] Triglycerides may fall with dapagliflozin (mean reduction approximately 10 mg/dL in DECLARE-TIMI 58), which modestly augments the lipid benefits of atorvastatin. [6]

Monitoring Parameters When Using Both Drugs

The following monitoring framework applies to patients starting or continuing both dapagliflozin and atorvastatin:

Renal Function and eGFR

Dapagliflozin efficacy depends on adequate renal function. The drug provides diminished glycemic benefit when eGFR falls below 45 mL/min/1.73m² and should not be initiated below 25 mL/min/1.73m² for the glycemic indication (though it may continue for heart failure or CKD indications at lower eGFRs per updated FDA labeling). [1] Check serum creatinine and eGFR at baseline, at 3 months, and at least annually thereafter. Severe renal impairment can raise atorvastatin concentrations independently, this is a drug-disease rather than drug-drug concern, but relevant in shared patients.

Fasting Lipid Panel

Check a fasting lipid panel 4 to 12 weeks after atorvastatin initiation or dose change, then annually. [4] The modest LDL rise from dapagliflozin does not typically require atorvastatin dose escalation, but documentation confirms treatment targets are met.

Muscle Symptoms

Ask about myalgia, muscle weakness, and dark urine at each follow-up visit. If a patient reports new or worsening muscle pain, check creatine kinase (CK). Because the dapagliflozin-atorvastatin pharmacokinetic interaction is small, overt myopathy attributable to this combination alone is not expected. Check for other interacting medications (azole antifungals, macrolide antibiotics, certain HIV protease inhibitors) that substantially raise CYP3A4-mediated atorvastatin exposure. [7]

Urogenital Symptoms and Glucose Monitoring

Dapagliflozin increases the risk of genital mycotic infections (incidence approximately 6 to 8% in women, 2 to 3% in men in the DECLARE-TIMI 58 trial). [6] Atorvastatin does not modify this risk. Monitor HbA1c every 3 to 6 months until stable, then every 6 to 12 months. [4]

Special Populations

Patients with Heart Failure

The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with HFrEF (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [13] Most DAPA-HF participants were on background statin therapy. No subgroup interaction between statin use and dapagliflozin benefit was reported, confirming that the two drugs work independently on their respective endpoints.

Patients with Chronic Kidney Disease

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced sustained 50% decline in eGFR, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001). [14] Atorvastatin is used routinely in CKD. Neither the DAPA-CKD supplemental material nor the FDA label for dapagliflozin flags atorvastatin as a concern in this population.

Elderly Patients (Age 65 and Older)

Volume depletion risk from dapagliflozin is modestly elevated in older adults, particularly those on diuretics. Atorvastatin is associated with a small increase in SAMS risk in patients over 65. Baseline CK is reasonable in elderly patients starting atorvastatin, though not mandated. The combination does not change this guidance.

What the FDA Labels Say

The FDA-approved prescribing information for dapagliflozin (Farxiga) includes a dedicated drug interaction section. [1] The label states that co-administration with atorvastatin increased atorvastatin Cmax by 4% and AUC by 22%. The label characterizes this as not clinically meaningful. No dose modification is recommended.

The atorvastatin (Lipitor) prescribing information identifies interacting agents by their CYP3A4 inhibitor potency. [7] Dapagliflozin is not listed. The label does not restrict co-administration with SGLT2 inhibitors.

Both labels were last updated in the 2024 prescribing information revision cycles. Clinicians should verify the current label via the FDA's Drugs@FDA portal when making prescribing decisions for patients with complex co-medication regimens.

Patient Counseling Points

Patients starting both drugs should hear three concrete messages.

Take both medications as directed. The 22% rise in atorvastatin exposure does not require dose changes, and no special timing separation between the two pills is necessary. Dapagliflozin is typically taken in the morning; atorvastatin can be taken at any time of day. [1] [7]

Report muscle symptoms promptly. Though the interaction does not meaningfully raise myopathy risk, any new unexplained muscle pain or weakness warrants a call to the prescribing clinician, because other medications in a complex regimen may be contributing.

Stay hydrated. Dapagliflozin causes mild urinary glucose and sodium excretion. Patients should drink adequate fluids, especially in hot weather or during illness, to prevent volume depletion. Atorvastatin does not contribute to this risk, but dehydration can independently raise creatinine and affect renal clearance of other drugs.

Summary of Interaction Classification

| Parameter | Finding | |---|---| | Pharmacokinetic interaction | Atorvastatin AUC +22%; dapagliflozin AUC unchanged | | Clinical significance | Not clinically meaningful per FDA label | | Dose adjustment | None required | | Contraindication | None | | Myopathy risk increase | Not clinically meaningful | | LDL-cholesterol net effect | Strongly favorable (atorvastatin benefit dominates) | | Blood glucose net effect | Favorable (dapagliflozin lowers glucose; atorvastatin raises slightly) | | Monitoring changes | Standard intervals for both drugs; no additional tests required |

Patients with type 2 diabetes, atherosclerotic cardiovascular disease, or CKD who need both an SGLT2 inhibitor and a statin should not delay or avoid the combination out of concern for this interaction. Check renal function per dapagliflozin guidelines [1] and a fasting lipid panel per ADA Standards of Care [4] at the recommended intervals.